United Laboratories International. has filed a patent for an oral preparation containing a JAK inhibitor and pharmaceutical excipients, designed for rapid dissolution. The formula (I) compound or its isomers, salts, or crystal form A are included. The process is simple and suitable for large-scale production. GlobalData’s report on United Laboratories International gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on United Laboratories International, Pressure swing adsorption was a key innovation area identified from patents. United Laboratories International's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Oral preparation with jak inhibitor for rapid dissolution
A patent application (Publication Number: US20240033255A1) discloses an oral preparation containing a JAK inhibitor, along with a pharmaceutical excipient. The JAK inhibitor includes a compound of formula (I), its isomers, pharmaceutically acceptable salts, or crystal form A. The formulation further specifies the selection criteria for various components, such as Ra, R1, R2, R3, R4, R5, R6, R7, R8, and L1, ensuring the precise composition of the oral preparation. Additionally, the patent application details the inclusion of fillers, disintegrants, adhesives, lubricants, and surfactants in the formulation to enhance its efficacy and stability.
Moreover, the patent application outlines the method for preparing the oral preparation, which involves techniques like wet granulation, dry granulation process, or powder direct pressing process. The content percentages of the JAK inhibitor, fillers, disintegrants, adhesives, lubricants, and surfactants are specified to ensure the optimal composition of the oral preparation. The application also highlights the potential therapeutic application of the oral preparation in treating autoimmune diseases like Rheumatoid arthritis, inflammatory bowel disease, and atopic dermatitis. By administering the disclosed oral preparation, a subject can benefit from the effective treatment of these conditions, showcasing the innovative approach proposed in the patent application.
To know more about GlobalData’s detailed insights on United Laboratories International, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
